Crispr Therapeutics is trading at $49.37, down 4.74%, amid a broad November 5 market sell-off, with the Nasdaq Composite down 3.23%.
- Third-quarter revenue was 24% below analyst estimates; loss per share was $1.15 versus $1.04 expected.
- Wells Fargo lowered its price target to $70 from $75 and maintained an Equal Weight rating.
- No fresh company-specific announcement directly explaining the November 5 move was identified.